Tirzepatide for Obesity Treatment and Diabetes Prevention
Authors' conclusion
Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo.
Study context
- Population
- Persons with obesity and prediabetes; treated 176 weeks, then 17-week off-treatment periodof 2539 randomised
- Participants
- 1,032 persons
- Comparison
- Once-weekly tirzepatide 5 mg, 10 mg or 15 mg vs placebo
Methodological detailsphase 3, double-blind, placebo-controlled
- Phase 3
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Percent change in body weight (key secondary end point) · week 176
Tirzepatide 5 mg
−12.3
mean · %
Tirzepatide 10 mg
−18.7
mean · %
Tirzepatide 15 mg
−19.7
mean · %
Placebo
−1.3
mean · %
P < 0.001 for all comparisons with placebo
Secondary outcomes
| Outcome | Placebo | HR (95% CI) | P value | |
|---|---|---|---|---|
| T2D after 17 weeks off treatment · 193 weeksTirzepatide (pooled)vs PlaceboKey secondary end point | 13.7% | 0.12 (0.1–0.2) | P < 0.001 | |
| 0.10.31310Hazard ratio (log scale) |
| Outcome | Placebo | HR (95% CI) | P value |
|---|---|---|---|
| Onset of T2D · 176 weeksTirzepatide (pooled) vs Placebo · key secondary end point | 13.3% | 0.07 (0.0–0.1) | P < 0.001 |
- Onset of T2D: Tirzepatide (pooled) 1.3%
- T2D after 17 weeks off treatment: Tirzepatide (pooled) 2.4%
Safety
Adverse events · 176 weeks
- Other than coronavirus disease 2019, most common AEs were gastrointestinal, mostly mild to moderate, occurring primarily during dose escalation in the first 20 weeks
- No new safety signals identified
Original publication
Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. Published 13 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →